Related Experiment Video
Updated: Jun 16, 2025
05:26
Author Spotlight: Innovations in iTUG Test for Enhanced Risk Assessment and Cognitive Insights
Published on: October 25, 2024
964
Letter to the Editor in Response to "Meta-Analysis of Fall Risk in Older Adults with Alzheimer's Disease"
Sheryl Zimmerman1, Glen L Xiong2, George Netscher3
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Cecil G. Sheps Center for Health Services Research, Program on Aging, Chronic Illness, and Long-Term Care, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Journal of the American Medical Directors Association
|August 20, 2024
Abstract
No abstract available in PubMed .
Related Concept Videos
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171